Drug Discovery Market Research Reports & Industry Analysis
Drug discovery is the systematic process of identifying, designing, and developing new pharmaceutical compounds or therapies to treat specific diseases or medical conditions. This is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will yield products that achieve regulatory approval by the Food & Drug Administration (FDA). To help stakeholders navigate this complex market, MarketResearch.com offers a suite of comprehensive drug discovery reports on industries big and small.
Understanding the Drug Discovery Market
- Our compilation of reports features thousands of reports from leading research firms, allowing you to access highly targeted information.
- We provide a rich repository of data, including analysis of drug discovery market trends, forecasts, growth opportunities, and strategies.
- We also provide expert commentary on disruptive technologies and the use of artificial intelligence, machine learning, and blockchain in drug discovery.
Informed Insights: Your Path to Success
Whether you're an industry professional, a consultant, or an executive, our research collection provides credible data to help you make informed decisions that catalyze growth. For decades, we have served top pharmaceutical companies, investment banks, and consulting firms as a trusted research partner. Uncover new opportunities and stay ahead of the curve with MarketResearch.com's drug discovery industry reports.
Drug Discovery Industry Research & Market Reports
-
Toll Like Receptor 8 (CD288 or TLR8) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Drugs In Development, 2022'; Toll Like Receptor 8 (CD288 or TLR8) pipeline Target constitutes close to 35 molecules. Out of which approximately 34 molecules are developed by companies and remaining by the universities/institutes. Toll Like ... Read More
-
Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... PAH or EC 1.14.16.1) pipeline Target constitutes close to 12 molecules. Out of which approximately 12 molecules are developed by Companies. The latest report GMDHC22040TDB - Phenylalanine 4 Hydroxylase - Drugs In Development, 2022, outlays ... Read More
-
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... or VEGFB) pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies. The latest report Vascular Endothelial Growth Factor B - Drugs In Development, 2022, outlays comprehensive information ... Read More
-
Epilepsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Epilepsy (Central Nervous System) pipeline landscape. Epilepsy is a neurological disorder characterized by the transmission of abnormal signals produced by a ... Read More
-
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... According to the recently published report 'Proto Oncogene Tyrosine Protein Kinase Src - Drugs In Development, 2022'; Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) ... Read More
-
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... 1 or JAK1 or EC 2.7.10.2) pipeline Target constitutes close to 53 molecules. Out of which approximately 53 molecules are developed by companies. The latest report Tyrosine Protein Kinase JAK1 - Drugs In Development, 2022, ... Read More
-
Aptamers: Therapeutics, Technologies, and Services Market, 2022-2035
... R&D initiatives focused on evaluating the potential of aptamers as theranostic agents. In the following year, the outstanding annual sales (USD 200 million) of the aforementioned product further bolstered the confidence of industry stakeholders in ... Read More
-
Traumatic Brain Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Traumatic Brain Injury (Central Nervous System) pipeline landscape. Traumatic brain injury happens when an external mechanical force ... Read More
-
Post-Operative Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Post-Operative Pain (Central Nervous System) pipeline landscape. Pain is one of the main postoperative adverse outcomes causing distress to ... Read More
-
Prader-Willi Syndrome (PWS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline landscape. Prader-Willi Syndrome (PWS) is a rare genetic disorder present at ... Read More
-
Iron Deficiency Anemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Iron Deficiency Anemia (Hematological Disorders) pipeline landscape. Anemia is a condition in which the body does not ... Read More
-
Acute Renal Failure (ARF) (Acute Kidney Injury) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Failure (ARF) (Acute Kidney Injury) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary ... Read More
-
Myasthenia Gravis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Myasthenia Gravis (Immunology) pipeline landscape. Myasthenia gravis is autoimmune neuromuscular disease characterized by weakness and rapid fatigue of any ... Read More
-
Cerebral Palsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Cerebral Palsy (Central Nervous System) pipeline landscape. Cerebral palsy is a group of disorders that can involve brain and ... Read More
-
Microscopic Polyangiitis (MPA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline landscape. Microscopic polyangiitis is an ill-defined autoimmune disease characterized by a systemic, ... Read More
-
Community Acquired Pneumonia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Community Acquired Pneumonia (Infectious Disease) pipeline landscape. Community-acquired pneumonia (CAP) is defined as pneumonia acquired outside a ... Read More
-
Male Hypogonadism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Male Hypogonadism (Male Health) pipeline landscape. Male hypogonadism is a condition in which the body doesn't produce enough testosterone. ... Read More
-
Hypoglycemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Hypoglycemia (Metabolic Disorders) pipeline landscape. Hypoglycemia is a condition characterized by an abnormally low level of blood sugar (glucose). Symptoms of ... Read More
-
Uterine Leiomyoma (Uterine Fibroids) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Uterine Leiomyoma (Non Malignant Disorders) pipeline landscape. Uterine fibroids are benign tumors that originate in the uterus ... Read More
-
Pressure Ulcers Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Pressure Ulcers (Dermatology) pipeline landscape. Pressure ulcers are an injury that breaks down the skin and underlying tissue. The ... Read More
-
Primary Immune Deficiency (PID) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Primary Immune Deficiency (PID) (Genetic Disorders) pipeline landscape. Primary immunodeficiency is defined as weaken immune ... Read More
-
Encephalomyelitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Encephalomyelitis (Central Nervous System) pipeline landscape. Encephalomyelitis is an inflammation of the brain and spinal cord. Encephalomyelitis can be caused by ... Read More
-
Amyloidosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Amyloidosis (Metabolic Disorders) pipeline landscape. Abnormal accumulation of amyloid protein in the tissues results in a group of diseases known as ... Read More
-
Drug Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Drug Addiction (Central Nervous System) pipeline landscape. Drug addiction, also called substance dependence or chemical dependency, is a disease ... Read More
-
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... (CIDP) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) pipeline landscape. Chronic inflammatory demyelinating ... Read More
Research Assistance
